AUS
NZ
UK
CA
USA
IND
_06_22_2026_08_42_48_769641.jpg)
Highlights
ONWARD Medical (LON:ONWD) meets key launch milestones for its ARC-EX System in the United States
Brain-computer interface platform records additional successful implants
Expanded clinical data reinforces sustained benefits of ARC-EX Therapy
ONWARD Medical N.V. (LON:ONWD), part of the FTSE AIM 100 Index, operates in the neurotechnology sector, developing therapies to restore movement and function in individuals with spinal cord injuries and other mobility impairments. The company recently issued its business update for the first quarter of the current year, highlighting commercial and technological advancements.
ARC-EX System Deployment
Following regulatory clearance in the United States, ONWARD Medical initiated the initial commercial phase for its ARC-EX System. The company has established a foundational field structure, which includes recruitment and training of personnel, implementation of a sales and service process, and partnerships with multiple reference clinics. Initial systems have been placed across key facilities, supporting the company's broader commercial strategy.
The response from early adopters and clinical users has been reported as positive. Feedback has contributed to confidence in achieving goals for the first half of the year. Additionally, ONWARD Medical secured access to leading federal procurement platforms, facilitating orders from the Department of Veterans Affairs and other government-linked entities.
Advancement of ARC-BCI and ARC-IM Technologies
Technological development remained a core focus during the quarter. The company's ARC-BCI platform recorded further milestones, including additional successful human implants. These implants are intended to support thought-driven movement, a critical step toward restoring voluntary mobility in people with severe motor impairments.
Simultaneously, ONWARD Medical introduced the ARC-IM Lumbar Lead in a clinical setting for the first time. This component of the investigational ARC-IM system is designed to assist with lower-limb mobility and represents an expansion of the company’s therapeutic scope.
Clinical Study Outcomes Reinforce Efficacy
The Pathfinder2 clinical study findings, published in a peer-reviewed journal focused on neuromodulation, provided new data on the ARC-EX Therapy. Participants who underwent extended treatment durations were observed to maintain and enhance motor function over time. These results support ongoing therapy access and reinforce the system’s role in long-term rehabilitation strategies.
Strategic Expansion and Market Presence
In a move to improve its accessibility to broader markets, ONWARD Medical established a sponsored Level 1 American Depositary Receipt program. This initiative supports its visibility in the United States and aligns with its transition from a clinical-stage to a commercially active company.
ONWARD Medical continues to emphasize its commitment to delivering transformative technologies in the neurostimulation field. The developments reported in the first quarter signal a focused execution of its multi-platform strategy aimed at restoring independence and function for individuals with severe mobility limitations.
